Antigen peptide T790M-6 and application to preparation of medicines for treating non-small cell lung cancer thereof

A kind of non-small cell lung cancer, T790M-6 technology, applied in the field of biomedicine

Active Publication Date: 2017-09-22
江苏迈健生物科技发展股份有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although some research reports indicate that immunotherapy targeting mutated antigens is feasible, ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antigen peptide T790M-6 and application to preparation of medicines for treating non-small cell lung cancer thereof
  • Antigen peptide T790M-6 and application to preparation of medicines for treating non-small cell lung cancer thereof
  • Antigen peptide T790M-6 and application to preparation of medicines for treating non-small cell lung cancer thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Prediction and Synthesis of Antigenic Peptide T790M-6

[0020] A recent analysis of motif methods showed that the SYFPEITHI supermotif method is an effective prediction system for HLA-A2 binding peptides. Therefore used to predict the 9-mer HLA-A2 binding peptide from EGFR-T790M. SYFPEITHI was used to remotely predict the HLA-A*02:01 restricted CTL epitope of EGF-T790M, and a decapeptide (LT S T V Q L I MQ) with a high score (10 points) was obtained.

[0021] The aforementioned antigenic peptides were prepared by chemical synthesis, that is, a very mature solid-phase peptide synthesis method well known in the art, and either the Boc method or the Fmoc method could be used. The specific method is to couple the protected amino acids to the inert solid phase carrier one by one, and then use strong acid to cleave the peptide chain from the carrier, and remove the side chain protection at the same time. A peptide whose amino acid sequence is L T S T V Q L I M Q is prepared...

Embodiment 2

[0023] 1. Peripheral blood mononuclear cell isolation experiment

[0024] Under sterile conditions, take 20 mL of fasting venous blood from HLA-A*02:01 positive normal healthy donors, use lymphocyte separation medium to separate mononuclear cells, and prepare cell suspension with a final mass concentration of 2×10 9 / L in a culture flask at 37°C, 5% CO 2 After incubating in the incubator for 2 hours, the non-adherent cells were washed away; the adherent cells (monocytes) were collected for later use.

[0025] 2. Mature DC induction and antigen loading

[0026] Add human granulocyte-macrophage colony-stimulating factor (rhGM-CsF) 1000mg / L, recombinant human interleukin-4 (rhIL-4) 500mg / L according to the final mass concentration of the above-mentioned monocytes, add the first 1 / 2 concentrations of cytokines, culture until the 5th day by adding (group A) antigen peptide, (group B) only add medium as a control group, at 37 ° C, 5% CO 2 Cultivate under the condition for 2 day...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides antigen peptide T790M-6 and application to preparation of medicines for treating non-small cell lung cancer thereof. The amino acid sequence of the antigen peptide T790M-6 is shown as SEQ ID NO. 1. The antigen peptide has a function of activating T cells to kill non-small cell lung cancer cells in targeting and provides a novel and promising immunotherapy method for non-small cell lung cancer patients (EGFR-TKIs therapy) in preventing and/or treating EGFR T790M mutations.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and specifically relates to antigenic peptide T790M-6 and its application in the preparation of medicines for treating non-small cell lung cancer. Background technique [0002] Lung cancer is the leading cause of cancer death worldwide. Non-small cell lung cancer accounts for 80% of lung cancer cases. Although the current treatment methods have been greatly developed, the prediction of lung cancer patients is still insufficient. Recently, however, important advances have been made in the treatment of this disease. In particular, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, have been developed as new treatments for specific non-small cell lung cancers, and these patients Mutations in the tyrosine kinase region of the EGFR gene. Preclinical studies using EGFR-TKI drugs on patients with EGFR-mutated non-small cell lung cancer (such...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/71A61K39/00A61P35/00
CPCA61K39/0011A61K2039/5154C07K14/71
Inventor 冷晓燕张超段云飞常菁曹巍虞强
Owner 江苏迈健生物科技发展股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap